MedTrace Logo

Imaging of Brain Receptors Using (11C)mGlu1

NCT01420952 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2019-12-16

No results posted yet for this study

Summary

Background:

\- (11C)mGlu1 is a new drug that helps to show where a protein, mGluR1, is found in the brain. The drug contains a small amount of radioactivity that can be detected by imaging studies like positron emission tomography (PET) scans. By looking at the mGluR1 receptors, researchers hope to better understand how they are involved in general health, brain disorders, and addiction.

Objectives:

* To test how (11C)mGlu1 is distributed in the brain and body.
* To measure how mGluR1 receptors display (11C)mGlu1 during imaging studies.

Eligibility:

\- Healthy volunteers between 18 and 50 years of age.

Design:

* Participants will be screened with a medical history, physical exam, and blood and urine tests. This study requires four visits to the NIH Clinical Center.
* Participants will have an initial evaluation, a magnetic resonance imaging (MRI) scan, a PET scan, and a final blood sample after the PET scan, all at different visits.
* The MRI and PET scans will focus on the brain. Participants will receive (11C)mGlu1, and have scans to see how it shows up in the brain.
* Some participants will have whole body imaging studies to see how (11C)mGlu1 shows up in the body.

Conditions

  • Dosimetry
  • Pharmacokinetics

Interventions

DRUG

[11C]LY2428703

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    lead NIH

Principal Investigators

  • Robert B Innis, M.D. · National Institute of Mental Health (NIMH)

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-07-29
Primary Completion
2012-11-27
Completion
2012-11-27

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01420952 on ClinicalTrials.gov